Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study

Figures & data

Table 1 Baseline Clinical Characteristics of the Study Population Before and After Propensity Score Matching

Variable	Before Propensity Score Matching			After Propensity Score Matching
	NOACs (n=825)	VKAs (n=625)	P-value	NOACs (n=495)	VKAs (n=495)	P-value
Age (years)	64.1±10.4	73.9±6.4	<0.001	63.3±10.1	64.1±9.9.	0.73
Female (%)	45.4	43.1	0.58	43.5	42.8	0.72
BMI (kg/m^2),	26.8±5.9	28.8±7.1	0.82	25.9±8.3	26.4±7.1	0.77
Hypertension (%)	48.6	58.2	0.001	50.2	53.1	0.57
CHA2DS2VASc score	2.6± 1.4	3.2± 1.5	0.02	2.3±0.4	2.2 ± 0.5	0.56
HAS-BLED score	2.5 ±1.1	3.3 ±1.0	0.001	2.4 ±1.1	2.1 ±1.5	0.55
Diabetes Mellitus (%)	16	25	0.06	13	14	0.4
Heart failure (%)	17.8	27.2	0.002	22.5	23.3	0.8
Previous stroke/TIA (%)	27.8	37.4	0.001	28.8	29.3	0.6
Previous MI (%)	8.2	13.1	0.01	5.6	6.2	0.7
CrCl (milliliter/minute)	71.3±12.1	60.5±12.9	0.001	70.3±21.1	71.2±21.2	0.7
Left atrial diameter (millimeters)	45.3±5.7	46.7±5.6	0.8	46.2±4.3	47.1±5.4	0.9
LAVI (milliliter/meter^2)	32.2±1.1	33.4±1.5	0.42	32.4±2.4	33.1±1.2	0.7
LV EF (%)	53.2±6.4	44.3±6.1	0.002	55.3±5.1	54.4±3.8	0.8
TEE performed (%)	100	100		100	100
Antiplatelets (%)	21	18	0.8	20	19	0.8
PPI (%)	88	85	0.5	86	84	0.5
Beta-blockers (%)	90	92	0.5	89	87	0.5
ACE-I or ARBs (%)	75	77	0.5	74	73	0.5

Notes: Values are expressed as mean ± SD unless otherwise stated.

Abbreviations: NOACs, non-vitamin K antagonist oral anticoagulants; SD, standard deviation; BMI, body mass index; LAVI, Indexed left atrial volume; MI, myocardial infarction; LV EF, left ventricular ejection fraction; TEE, transesophageal echocardiogram; TIA, transient ischemic attack; CrCl, creatinine clearance; PPI, proton pump inhibitors; ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptors blockers.

Table 2 Safety and Effectiveness Endpoints and Anticoagulant Treatment Discontinuation Rate in the NOACs and VKAs Groups

Variable	NOACs	VKAs	P value
	(n = 495)	(n = 495)
Stroke/SE/TIA	0.6%	0.8%	0.7
Major Bleedings	1.01%	1.4%	0.5
All-cause mortality	0.6%	0.8%	0.7
CRNMB	1.2%	2.2%	0.2
ICH	0.2%	0.4%	0.6
GIB	0.8%	1.01%	0.7
Anticoagulant therapy discontinuation rate	1.6%	3.6%	0.04

Abbreviations: SE, systemic embolism; TIA, transient ischemic attack; CRNMB, clinically non relevant major bleedings; ICH, intracranial hemorrhages; GIB, gastrointestinal bleedings.

Figure 1 Kaplan Meier survival curve analysis estimating the risk of major bleedings in VKA and NOAC groups.

Figure 2 Kaplan Meier survival curve analysis estimating the risk of thromboembolic events in VKA and NOAC groups.

Figure 3 Kaplan Meier survival curve analysis estimating the risk of overall mortality in VKA and NOAC groups.